Avid Bioservices Inc (CDMO)

[biopharm]

Immune Ventures to Inmune Bio ...all tied to Xencor and Merck

I wonder how John Springs Stafford is doing these days, has he responded to any calls lately ?

Name and Address(1)

Common Stock
Owned


Number of
Shares Exercisable Within 60 Days

Percentage of Common Stock

Executive Officers and Directors

Raymond J. Tesi
1,503,333
255,554
(1)(2)
20.17 %

David J. Moss
1,186,667
255,554
(1)(3)
16.54 %

Mark Lowdel
1,503,333
183,326
(1)(4)
19.34 %

Tim Schroeder
166,667
24,000
(5)
2 %

J. Kelly Ganjei
24,000
(6)
*%

David Szymkowski
1,585,000
108,000
(7)
19.42 %

Scott Juda, JD
24,000
(10)
*%

Officers and Directors as a group (7 individuals)

5,945,000
874,434
78.21 %

Beneficial owners of more than 5%

Toucan Capital Fund III (8)
700,000
8 %

Xencor Inc. (9)
1,585,000
18.18 %


Looks like Xencor likes Inmune that both like PS Targeting ...
____________


John S Stafford and Bruce Carter voted into Xencor BOD 2015

Mirati BOD Bruce Carter ties Rolf Brekken and now wonder why Mirati racing for approval now


____________________


ISSUER: Xencor, Inc.
TICKER: XNCR CUSIP: 98401F105

MEETING DATE: 6/9/2015

FOR/AGAINST
PROPOSAL: PROPOSED BY VOTED? VOTE CAST MGMT





PROPOSAL #1.1: ELECT DIRECTOR BRUCE L.A. CARTER ISSUER YES FOR FOR
PROPOSAL #1.2: ELECT DIRECTOR ROBERT F. BALTERA, JR. ISSUER YES FOR FOR
PROPOSAL #1.3: ELECT DIRECTOR BASSIL I. DAHIYAT ISSUER YES FOR FOR
PROPOSAL #1.4: ELECT DIRECTOR JONATHAN FLEMING ISSUER YES FOR FOR
PROPOSAL #1.5: ELECT DIRECTOR KURT GUSTAFSON ISSUER YES FOR FOR
PROPOSAL #1.6: ELECT DIRECTOR A. BRUCE MONTGOMERY ISSUER YES FOR FOR
PROPOSAL #1.7: ELECT DIRECTOR JOHN S. STAFFORD, III ISSUER YES FOR FOR
PROPOSAL #2: RATIFY BDO USA, LLP AS AUDITORS ISSUER

_____

Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function
Walaa E Kattan, Wei Chen, Xiaoping Ma, Tien Hung Lan, Dharini van der Hoeven, Ransome van der Hoeven, View ORCID ProfileJohn F Hancock Correspondence email
Published 26 August 2019


https://www.life-science-alliance.org/content/2/5/e201900431

____

Feb 2019

https://med.uth.edu/news/2019/02/04/patent-protects-new-role-for-old-drug-that-shows-promise-for-fighting-cancer/


The patent is on both the screening method and the new use for fendiline as an anti-cancer therapeutic. The next step is to improve the drug in ways that make it more efficacious and marketable.

Patent protects new role for old drug that shows promise for fighting cancer
Dr. Dharini van der Hoeven of the School of Dentistry and Dr. John F. Hancock of The Brown Foundation Institute of Molecular Medicine at UTHealth, share a patent on a new approach for treating cancer. Photo by Dwight C. Andrews.


UTHealth Houston has patented a new approach for treating cancer by targeting a mutation found in up to 25 percent of cancers overall and implicated in about 50 percent of cancer deaths.

The patent, "Method and Composition for Use in K-RAS Mediated Disorders," represents a discovery that could change survival rates in a wide variety of hard-to-treat cancers.

â??Ninety-five percent of pancreatic cancers are due to the K-RAS mutation,â? said UTHealth School of Dentistry Associate Professor Dharini van der Hoeven, PhD, MSc, who shares credit for the patent with her mentor, John F. Hancock,MA, MB, BChir, PhD, ScD, professor and chair, Department of Integrative Biology and Pharmacology at McGovern Medical School at UTHealth, vice dean of research, and executive director of the Brown Foundation Institute of Molecular Medicine.

The key is an old drug, fendiline, used in the past to treat angina and other cardiac conditions. In animal studies, fendiline inhibited the K-RAS protein, which in turn inhibited cancer. It has not yet been tested as a cancer treatment for humans.

Van der Hoeven was a research fellow in Hancocks lab at the medical school when she and another fellow, Kwang-Jin Cho, PhD, began screening small-molecule libraries using a novel, high-throughput screening method they developed to look for compounds that might inhibit K-RAS, a target chosen because of its prevalence in cancer.

"Using this method, we screened entire drug libraries, close to 30,000 molecules," van der Hoeven said. Fendiline was one of the molecules identified that showed great promise for inhibiting K-RAS.

It was a promise that held up in animal studies.

The patent is on both the screening method and the new use for fendiline as an anti-cancer therapeutic. The next step is to improve the drug in ways that make it more efficacious and marketable. Funding so far has come from the Cancer Prevention and Research Institute of Texas, with Hancock as principal investigator and van der Hoeven as co-investigator.

Van der Hoeven is also investigating use of fendiline on oral cancers, which express H-RAS, a different isoform of mutated RAS. Early results have been exciting, she said.

"To contribute to something like this, for me, is more than getting the patent and the potential collaborating with pharmaceutical companies," she said. "Its about discovering something that could potentially help people who suffer so much from cancer. Thats what gives me fulfillment."